Most Popular Stories
- Hospitals lose reimbursement for 'unnecessary' ER visits
- Healthcare jobs will grow the fastest of all industries
- Online tools, social media ease clinical recruiting, research
- Hospital exec arrested in $116M Medicare scheme
- Docs not always honest with patients
- Medicaid cuts loom despite overdue reimbursements
Featured Jobs
-
Epic Ambulatory Beacon Consultant
Meditology Services - NC -
ICD-10 Revenue Cycle, Manager
Meditology Services - Atlanta, GA -
Electronic Health Records Application Support Manager RN-New Year New Career
Avanti on behalf of Respected Health System - San Francisco, CA
Events
- IHI's Breakthrough Series College
April 11-13, 2012 — Cambridge, MA - AHIP's Institute 2012
June 20-22 — Salt Lake City, UT - 3rd Healthcare IT Innovation Asia
Mar 14-15 2012 — Singapore - Medical Devices Summit 2012
March 6-7 2012 — The Boston Park Plaza Hotel & Towers, Boston, MA
Paid Research Reports
- Electronic health records: getting it right first time
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Stakeholder Opinions: Ophthalmology - Leading brands under threat
- Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
- Healthcare Regulatory Update: The United Arab Emirates
- Point of Care Testing: Evaluating the return to evidence based medicine, novel technologies and the competitive landscape
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 50,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
Fourth Vioxx trial begins
The latest Vioxx trial opened in Atlantic City, New Jersey on Monday. Houston lawyer W. Mark Lanier hopes to repeat last year's win in a Texas courtroom. Thomas Cona of Cherry Hill blames his heart attack on the painkiller, as does fellow plaintiff John McDarby. Merck withdrew Vioxx from the market in 2004 after a study showed the drug doubled the risk of heart attacks and strokes if taken for an eighteen month. The drugmaker is expected to argue that neither Cona or McDarby took the drug long enough to have been at risk. Legal analysts doubt that Lanier's folksy style will play well on Merck's home turf.
- see this article from The Washington Post
Related Stories
- Gilmartin testifies in Vioxx suit
- Vioxx verdict shocks markets
- Pivotal week in Vioxx trial
- Merck doctor testifies in Vioxx trial
- FL sues Merck over Vioxx marketing
- Despite safety issues, Vioxx still in demand
- SPOTLIGHT: Hung jury forces mistrial in Vioxx suit
- Metric: Brand drug prices surge ahead of inflation rate
- Merck liability climbs after ruling
- Merck documents may worsen company's case
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map
| Editors | List in Marketplace | Supplier in MarketplaceTHE FIERCEMARKETS NETWORKFierceEnergy | FierceSmartGrid | FierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceHealthPayer | FiercePracticeManagement | FierceEMR | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceGovernment | FierceHomelandSecurity | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceMedicalDevices | FierceDrugDelivery | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceEnterpriseCommunications | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe | FierceCable© 2011 FierceMarkets. All rights reserved. |
![]() |
